全文获取类型
收费全文 | 13749篇 |
免费 | 1744篇 |
国内免费 | 315篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 146篇 |
妇产科学 | 100篇 |
基础医学 | 562篇 |
口腔科学 | 157篇 |
临床医学 | 2096篇 |
内科学 | 1217篇 |
皮肤病学 | 276篇 |
神经病学 | 584篇 |
特种医学 | 444篇 |
外国民族医学 | 9篇 |
外科学 | 764篇 |
综合类 | 2285篇 |
预防医学 | 1344篇 |
眼科学 | 189篇 |
药学 | 3109篇 |
68篇 | |
中国医学 | 1559篇 |
肿瘤学 | 850篇 |
出版年
2024年 | 82篇 |
2023年 | 318篇 |
2022年 | 598篇 |
2021年 | 931篇 |
2020年 | 976篇 |
2019年 | 632篇 |
2018年 | 583篇 |
2017年 | 784篇 |
2016年 | 762篇 |
2015年 | 623篇 |
2014年 | 1507篇 |
2013年 | 1431篇 |
2012年 | 1065篇 |
2011年 | 896篇 |
2010年 | 753篇 |
2009年 | 566篇 |
2008年 | 447篇 |
2007年 | 458篇 |
2006年 | 408篇 |
2005年 | 374篇 |
2004年 | 278篇 |
2003年 | 248篇 |
2002年 | 169篇 |
2001年 | 156篇 |
2000年 | 123篇 |
1999年 | 88篇 |
1998年 | 83篇 |
1997年 | 48篇 |
1996年 | 54篇 |
1995年 | 54篇 |
1994年 | 40篇 |
1993年 | 30篇 |
1992年 | 33篇 |
1991年 | 29篇 |
1990年 | 24篇 |
1989年 | 18篇 |
1988年 | 20篇 |
1987年 | 13篇 |
1986年 | 15篇 |
1985年 | 21篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 5篇 |
1981年 | 8篇 |
1980年 | 9篇 |
1979年 | 9篇 |
1978年 | 5篇 |
1974年 | 5篇 |
1973年 | 3篇 |
1972年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Functional recovery, the goal of treatment, has long been overlooked in the assessment of effectiveness of pharmacological treatments. However, with the recent shift in paradigm, from syndromal–symptomatic recovery to functional recovery, there appears to be a new interest in the definition and evaluation of functional recovery. Since functional recovery lags symptomatic recovery, sometimes by months or years, the attainment of functional recovery will be determined by both efficacy and long-term compliance. Quetiapine, due to its efficacy in both mania and depression, and effect on cognition may lead to improved functioning in patients with bipolar disorder. 相似文献
22.
23.
赵法军 《中国烧伤创疡杂志》2006,18(4):287-289
目的:探讨口腔、咽、食管烧伤的治疗方法。方法:对2000年3月-2005年12月,采取口服湿润烧伤膏(MEBO)治疗的25例患者进行回顾性资料总结。结果:25例病人均治愈,无创面感染、食管狭窄、腹泻等并发症。结论:MEBO对口腔、咽、食管等上消化道部位黏膜烧伤疗效确切,方法简单易行。 相似文献
24.
卵巢恶性肿瘤与血小板增多关系分析 总被引:1,自引:0,他引:1
李洁华 《中国现代医药杂志》2005,7(5):48-49
目的探讨卵巢恶性肿瘤伴发血小板增多的临床规律。方法回顾分析98例卵巢恶性肿瘤患者的临床资料,26例合并血小板增多。结果血小板增多占26.5%,其中晚期(Ⅲ+Ⅳ期)占88.46%,晚期患者血小板偏高明显增多,且肿瘤切除后血小板下降。结论卵巢恶性肿瘤伴发血小板增多晚期患者多见,预后差,血小板增多可作为判断卵巢肿瘤恶性程度及术后随访的指标。 相似文献
25.
仙草消毒液为含 3 0 %乙醇的植物消毒剂 ,其中包括五味子、细辛、丁香等成分 ,p H6.0 1。为了解其杀灭微生物效果及其毒性 ,进行了载体定量杀菌试验及毒性试验。结果 ,1∶ 1的水稀释液对金黄色葡萄球菌作用2分钟 ,1∶ 2的稀释液对金黄色葡萄球菌作用 8分钟 ,以其原液对白色念珠菌作用 2 min,平均杀灭率均大于99.90 %。小牛血清对其杀灭效果有影响 ,原液经 5 4℃存放 14天 ,杀菌效果无明显变化。以其原液对雌、雄小鼠经口 LD50 >5 0 0 0 mg/Kg,对大耳白兔一次眼、皮肤刺激试验平均积分指数为 0 ,微核试验阴性 ,蓄积毒性试验为弱蓄积毒性 相似文献
26.
影响利培酮治疗精神分裂症疗效因素分析 总被引:7,自引:2,他引:5
目的 探讨影响利培酮对精神分裂症疗效的关键因素。方法 对 57例单用利培酮治疗的精神分裂症患者 ,采用一系列标准评定工具对 39个临床指标进行定量或半定量评估。并作Logistic回归分析。将治疗后简明精神病评定量表 (BPRS)减分率≥ 30 %者确定为“有效”。结果 单因素分析显示 :服药依从性 ,MMPI中Sc、Si、D因子 ,治疗前BPRS 2和BPRS 4因子 ,TESS 3因子 ,家族史 ,起病形式 ,意识模糊 ,住院时间与利培酮疗效有关 ;经多因素分析有服药依从性 ,MMPI(Sc) ,BPRS 2 ,家族史 ,意识模糊等 5个指标选入回归方程。结论 影响利培酮对精神分裂症疗效的关键因素依次为服药依从性 ,MMPI中精神分裂因子 ,阴性症状 ,家族史及意识模糊 相似文献
27.
28.
Psoriasis is a chronic inflammatory condition that often requires life-long treatment. Conventional therapies have not fully met the needs of psoriatic patients, because of limited efficacy, adverse effects with cumulative use, and patient inconvenience. In the past decade, biologic immunotherapies have become accepted treatments for psoriasis as a result of perceived efficacy and safety on the part of patients and practitioners. However, most data on these medications come from relatively limited short-term trials. In this review, we will focus on the available long-term data on the efficacy of the biologic agents. We will emphasize the strengths and weakness of the available data of the biologic agents that are Food and Drug Administration (FDA)-approved for the treatment of moderate to severe psoriasis (alefacept, efalizumab, * etanercept, infliximab, and adalimumab), with the inclusion of a newer agent currently under FDA evaluation (ustekinumab). 相似文献
29.
J.-P. Ortonne A. Taïeb A.D. Ormerod† D. Robertson‡ J. Foehl‡ R. Pedersen‡ C. Molta‡ B. Freundlich‡ 《The British journal of dermatology》2009,161(5):1190-1195
Background Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses.
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care. 相似文献
30.
冬凌草单药及与化疗合用治疗食管癌205例 总被引:1,自引:0,他引:1
目的:观察冬凌草单药及与化疗合用治疗食管癌的临床疗效.方法:448例患者,均经病理细胞学和X线检查确诊为食管癌.其中早期癌76例,均采用冬凌草单药治疗.晚期癌372例,167例采用冬凌草单药治疗,205例采用冬凌草与化疗合用.结果:用冬凌草单药治疗早期食管癌患者3,5,10,13 a的生存率明显高于未治疗组(98.68% vs 51.52%,84.02% vs 28.62%,63.49% vs 11.45%,50.13% vs 8.59%;P<0.001).对于晚期食管癌,冬凌草联合化疗应用,其总有效率明显高于以PYM(BLM)为基础的单一化疗(66.82% vs 42.85%,P<0.01).冬凌草与化疗合用组与单一化疗对照组相比副作用基本相同,无明显差异(P>0.05).结论:对于早期食管癌患者,冬凌草能控制疾病发展延长生存时间;对于晚期食管癌患者,冬凌草能增强化疗的作用. 相似文献